Advertisement
Merriman Curhan Ford & Co. will act as underwriter and book-runningmanager for the proposed offering. This offering will be made only by means ofa prospectus. When available, copies of the prospectus relating to thesesecurities may be obtained from: Merriman Curhan Ford & Co., 600 CaliforniaStreet, 9th Floor, San Francisco, CA 94108, Telephone 415-248-5600,Fax 415-248-5690.
Advertisement
A registration statement relating to these securities has been filed withthe Securities and Exchange Commission but has not yet become effective.These securities may not be sold nor may offers to buy be accepted prior tothe time the registration statement becomes effective. This press releaseshall not constitute an offer to sell or the solicitation of an offer to buy,nor shall there be any sale of these securities in any state in which suchoffer, solicitation or sale would be unlawful prior to registration orqualification under the securities laws of any such state.
About Neurobiological Technologies, Inc.
NTI is a specialty biopharmaceutical company with expertise in identifyingand acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. The Company iscurrently developing Viprinex (ancrod), a novel reperfusion agent that is inpivotal Phase 3 trials for the treatment of acute ischemic stroke.
SOURCE Neurobiological Technologies, Inc.
